Tier 4 — mechanistic
α-Ketoglutarate inhibits autophagy
Aging (Albany NY)
2019
11(11):3418-3431
Bibliography
- PubMed
- PMID 31173576
- PubMed Central
- PMC6594794
- Funding
- Supported by European and French cancer/aging research programs, ERC and associated academic grants; NAWI Graz and BioTechMed-Graz also supported the work.
- Competing interests
- Guido Kroemer and Frank Madeo disclosed being scientific cofounders of Samsara Therapeutics.
Study snapshot
| Design | Mechanistic cell-culture, metabolomics and yeast experiments comparing membrane-permeable AKG esters. |
|---|---|
| Model | Human and mammalian cell systems plus yeast; no oral supplementation cohort. |
| Sample | Laboratory experiments across multiple cell systems; no clinical cohort. |
| Intervention | Dimethyl-, trifluoromethylbenzyl- and octyl-AKG esters used to manipulate intracellular AKG. |
| Duration | Acute laboratory exposure protocols. |
| Endpoints | Autophagic flux; Cellular metabolism; ATP and metabolite changes; mTOR-related signaling |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- Ca-AKG and autophagy: what the evidence actually showsCa-AKG and autophagy: AKG activates autophagy in some worm, fly, brain-slice and immune-cell models but inhibits it in other systems. Human oral...Read analysis
- How does Ca-AKG work? Mechanisms explainedHow Ca-AKG works: the TCA cycle, TET/JmjC enzymes, ATP synthase/TOR, AMPK, immune signaling, senescence, OXGR1 and the conflicting autophagy evidence.Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified



